Monoclonal gammopathy of renal significance: Multidisciplinary approach to diagnosis and treatment

Sabine Karam, Mohammad Haidous, Iman Abou Dalle, Amélie Dendooven, Nour Moukalled, Amaryllis Van Craenenbroeck, Ali Bazarbachi, Ben Sprangers

Research output: Contribution to journalReview articlepeer-review


Monoclonal gammopathy of renal significance (MGRS) is a hemato-nephrological term referring to a heterogeneous group of kidney disorders characterized by direct or indirect kidney injury caused by a monoclonal immunoglobulin (MIg) produced by a B cell or plasma cell clone that does not meet current hematologic criteria for therapy. MGRS-associated kidney diseases are diverse and can result in the development of end stage kidney disease (ESKD). The diagnosis is typically made by nephrologists through a kidney biopsy. Many distinct pathologies have been identified and they are classified based on the site or composition of the deposited Mig, or according to histological and ultrastructural findings. Therapy is directed towards the identified underlying clonal population and treatment decisions should be coordinated between hematologists and nephrologists in a multidisciplinary fashion, depend on the type of MGRS, the degree of kidney function impairment and the risk of progression to ESKD.

Original languageEnglish (US)
Article number103926
JournalCritical Reviews in Oncology/Hematology
StatePublished - Mar 2023

Bibliographical note

Publisher Copyright:
© 2023


  • Chemotherapy
  • MGRS
  • MGUS
  • Monoclonal protein

PubMed: MeSH publication types

  • Journal Article
  • Review


Dive into the research topics of 'Monoclonal gammopathy of renal significance: Multidisciplinary approach to diagnosis and treatment'. Together they form a unique fingerprint.

Cite this